Effect of sodium–glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial

• Published in: International urology and nephrology Vol. 55; no. 9; pp. 2321 - 2326
• Main Authors: Hammad, Hany, Shaaban, Asmaa, Philips, Mariana Victor, Fayed, Ahmed, Abdelaziz, Tarek Samy
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.09.2023; Springer Nature B.V
• Subjects: Antidiabetics; Creatinine; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - drug therapy; Double-Blind Method; Epidermal growth factor receptors; Glomerular Filtration Rate; Glomerulonephritis; Glomerulonephritis - complications; Glomerulonephritis - drug therapy; Glucose transporter; Humans; Immunosuppression; Kidney; Kidney diseases; Medicine; Medicine & Public Health; Nephrology; Nephrology - Original Paper; Placebos; Proteinuria; Proteinuria - drug therapy; Proteinuria - etiology; Remission; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Statistical analysis; Treatment Outcome; Urology; Glomerulonephritis; Empagliflozin; Sodium–glucose transporter inhibitors; Diabetes mellitus; Proteinuria

Background Amelioration of proteinuria is one of main treatment targets in patients with glomerulonephritis, yet the remission rates are suboptimal. Aim of the study To examine the effect of the sodium–glucose transporter 2 inhibitor (empagliflozin) on proteinuria and kidney function progression, in...